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Abstract
Background: Despite its low cure rates and possible resistance, praziquantel (PZQ) is the only drug available for
schistosomiasis treatment. Hence, monitoring its efficacy is crucial. This study assessed the efficacy of PZQ,
determined re-infection and incidence rates of Schistosoma haematobium infection among school-going children in
the Ndumo area, KwaZulu-Natal.
Methods: A cohort of 320 school-going children (10 – 15 years) in 10 primary schools was screened for S.
haematobium infection using the filtration technique. Infected children were treated at different times and hence
were divided into two sub-cohorts; A1 and A2. Non-infected children constituted the sub-cohort B. Children who
continued excreting viable eggs 4 weeks post-treatment received a second dose of PZQ. Re-infection rates were
determined in sub-cohort A1 and A2 at 28 and 20 weeks post-treatment, respectively. Cure rates (CR) and egg
reduction rates (ERR) were calculated. Incidence rate was assessed 28 weeks post baseline survey using children
that were negative for schistosome eggs at that survey. Analysis of data was done using the Chi square and the
Wilcoxon rank test. A 95% confidence interval with a P-value < 0.05 determined significance.
Results: At baseline, 120 (37.5%) of the 320 study participants were found infected with Schistosoma haematobium.
Heavy infections accounted for 36.7%. The calculated cure rates were 88.07% and 82.92% for females and
males, respectively. Egg Reduction Rates of 80% and 64% for females and males were observed 4 weeks after
the initial treatment. After the second treatment, CR was 100% in females and 50% in males with an ERR of
100% in females and 70% in males. At 20 and 28 weeks post treatment, reinfection rates of 8.03% and 8.00%
were observed, respectively, giving an overall rate of 8.1%. An incidence rate of 4.1% was observed 28 weeks
after the baseline screening.
Conclusions: The study indicated high CR while the ERR was low suggesting a reduced PZQ efficacy. The
efficacy improved among females after the second dose. Re-infection rates at 20 and 28 weeks post-
treatment were low. The study also indicated a low incidence rate for the 28 weeks period.
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Background
Worldwide, urinary and intestinal schistosomiasis
continue to be public health problems in tropical and
sub-tropical areas [1]. An estimated 779 million
people are exposed to the infection and the highest
burden of the disease is in Africa, particularly the
sub-Saharan region that accounts for roughly 90% of
the infection [2]. Globally, in 2012 at least 249
million required preventive treatment but only 42.1
million were treated. Among those treated, 84.5%
were in African countries [3, 4]. The number of
treated people increased to 61.6 million in 2014,
representing 20.7% of those requiring preventive treat-
ment. Of the 49.2 million children treated, 43.3
million (83.4%) were in the African region [5]. The
number of people needing annual treatment in South
Africa was recently indicated to be 5.2 million [6].
In endemic areas, people contract schistosome infec-
tions during activities that bring them in contact with
water infested with cercaeriae released by intermedi-
ate host snails [1, 4]. Supply of potable water, im-
provement of sanitation combined with preventive
chemotherapy using praziquantel are considered the
mainstay strategies to curb the burden of schisto-
somiasis [4]. Environmental concerns and high costs
associated with control of intermediate host snails
have hindered the achievement of a successful overall
schistosomiasis control strategy [7]. Nevertheless,
Brazil, Cambodia, Egypt, China and the Philippines
have made satisfactory progress in reducing morbidity
and mortality due to schistosomiasis [8].
To date, praziquantel administered at the standard
oral single dose of 40 mg/kg body weight is the only
drug recommended by WHO for preventive chemo-
therapy [1, 4]. Studies have indicated that it drastically
reduces morbidity and transmission of schistosomiasis
with a high cure rate (CR) and satisfactory egg reduc-
tion rate (ERR) [9, 10]. Few reports of treatment
failures have been reported with praziquantel in en-
demic areas [10, 11].
Drug trial studies comparing the use of the recom-
mended regimen of 40 mg/kg to 60 mg/kg single
dose found that both regimens had comparable effi-
cacy [12, 13] with the 60 mg/kg dose having a signifi-
cantly higher rate of mild and transient side effects
than the 40 mg/kg dose [12]. Hence, a dose of
60 mg/kg split in two equal doses has been suggested
in treatment to prevent side effects and to kill imma-
ture worms [14].
Controversies about the use of a repeated dose
within 2–8 weeks following the initial dose of prazi-
quantel have arisen [15]. Notably, higher parasito-
logical improvements were observed after a repeated
second dose than it was after at the first dose; and
the cure rate also differed between species, being
higher for S. mansoni than for S. haematobium [15].
However, praziquantel is only active on adult worms
but not on immature worms [16]. Thus, a com-
bination of praziquantel with antimalarial drugs
(artemether, artesunate) possessing anti-schistosome
properties of killing immature worms has been
suggested [16, 17].
Rapid assessment of incidence in a community is
significantly sensitive for indicating periodic lapses in
the quality control [18]. Despite the efficacy of
praziquantel at the standard dose, rapid re-infections
have been reported [19, 20]. Factors such as socio-
demography [21], level of schistosomiasis prevalence
[22], and seasonal variations [23] in the area have
been reported to influence the re-infection and inci-
dence rates.
Schistosomiasis is endemic in South Africa, par-
ticularly in the KwaZulu-Natal (KZN) province. The
Department of Health in collaboration with the
Department of education implemented a national
helminth control program promoting regular treat-
ment for schistosomiasis and soil transmitted hel-
minths in all primary schools between 1997 and
2000 [23, 24]. uMkhanyakude is among districts
with the a very high burden of schistosomiasis [25]
in KZN province. Prevalence of 68% and 16.6%
were reported in 1998 in the northernmost part and
southernmost part of the district, respectively [23,
26]. A study conducted in 2011 in the Ugu district
of KwaZulu-Natal reported that 44.3% of school
going children were reached during a mass tre-
atment campaign implemented by the provincial
Department of Health [6].
Although prevalence and spatial distribution of
schistosomiasis have been reported in the district,
less emphasis has been given to the efficacy of
praziquantel and the subsequent re-infection rates
following treatment in uMkhanyakude district. In-
formation on the efficacy of praziquantel and the
infection rates may help in evaluating policies and
strategies that guide schistosomiasis control activ-
ities in the district, particularly in the Ndumo area.
Moreover, the existing data might need to be up-
dated since the last study that assessed efficacy of
PZQ in the area was about 18 years ago [23]. Thus,
we investigated the efficacy of praziquantel, the re-
infection and incidence rates among school-going
children aged 10 – 15 years.
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Methods
Study area and population
This study was conducted in Ndumo area located at the
northernmost part of uMkhanyakude district in
KwaZulu-Natal (KZN) province, South Africa (Fig. 1).
The district extends over 12 818 km2 limited to the East
by the Indian ocean, to the West by Zululand district, to
the North by Mozambique, to the Northwest by
Swaziland, and to the South by uThungulu district [27].
uMkhanyakude district is generally arid with a sub-
tropical climate characterised by a hot and humid
summer (November – February); and a cooler and drier
winter (June – August). Its hydrologic network is consti-
tuted by rivers (e.g. mainly Ingwavuma and Pongola),
streams, dams (e.g. Pongola) and ponds [25]. There is
limited access to piped water [28]. Thus, people rely on
open sources of water (river and dams) to sustain their
daily domestic needs of water [27]. The unemployment
rate is high; 46.18% in 2003 [27] and 53.00% in 2010
[25]. Moreover the district, particularly the Ndumo area
is considered as the gateway from Mozambique to South
Africa [29]. Thus imported cases of schistosomiasis are
likely to come in through Mozambique, one of the
countries with the highest burden of schistosomiasis
worldwide [4]. uMkhanyakude district also has the high-
est prevalence of HIV infection and schistosomiasis
infection in the country [25].
Study design and sampling
A prospective cohort of 10–15 years old school-going
children whose parents signed consent forms and the
children assented constituted the study sample. Study
participants were randomly sampled from all primary
schools located (Fig. 1) in the Ndumo area (10). They
were initially screened for schistosomiasis at the end of
June 2015 and follow up screening was done in early
March 2016 (Fig. 2).
A sample size of 246 primary school-going children
was determined using the formula as described by




Where Z statistic is 1.96 for the confidence level of
95%; P is 0.8 as the expected proportion of the
Fig. 1 Map of Ndumo area and coordinates of surveyed schools, uMkhanyakude district, South Africa, adapted from Manyangadze et al. [28]
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characteristic to be measured in the study area [25]; d is
the precision of 0.05 for 95% confidence interval.
Since it was a prospective study, attritions were
expected for various reasons; unsigned consent and
assent forms, absence of participants at school dur-
ing the day of screening, failure to provide urine
sample or not being available during subsequent
surveys. We therefore multiplied N (246) by 2.5 to
estimate the baseline sample size of the study at 615
of which only 320 children participated in the study.
School registers were used to randomly select the
study participants taking into account the sex ratio.
Children that were screened for S. haematobium in
the initial pre-treatment survey were divided into 2
cohorts A and B. Cohort A comprised of participants
that were initially found positive for S. haematobium
infection. They were treated and followed-up to
determine praziquantel efficacy and re-infection.
However, because of challenges associated with treat-
ment logistics, cohort A was divided into two sub-
cohorts. Sub-cohort A1 included children from five
primary schools treated in July 2015 and sub-cohort
A2 included children from the other five schools
treated in September 2015. Thus, sub-cohort A1 was
rescreened 28 weeks post treatment while sub-cohort
A2 was rescreened after 20 weeks to determine the
re-infection rate. Cohort B included school-going
children that were initially negative and re-screened




At each survey study participants were asked to
provide 50 ml of urine in plastic containers between
10 AM and 2 PM, the likeliest time to get high
load of eggs [31]. The urine samples were stored in
wooden boxes with a lid under a shade to protect
them from the sunlight until the time of processing
and examination on the same day. Ten millilitres of
urine were examined using the filtration technique
for detection of S. haematobium eggs [31, 32].
Given the difference in the treatment period
(8 weeks) which led to differences in the period of
exposure of sub-cohort A1 and A2, re-infection
cases were determined at week 28 post treatment in
sub-cohort A1; and at week 20 post treatment in
sub-cohort A2. Another parasitology survey was
Fig. 2 Schematic diagram of the study design
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conducted to detect new cases of infection (incidence) in
cohort B at 28 weeks from the baseline.
Treatment with Praziquantel
Treatments of infected children at the 10 primary
schools was done by nurses based at local clinics of
the Jozini municipality Department of Health with
the assistance of the research team. The first and
second treatments were done in July and September
2015 for sub-cohort A1, and in August and October
2015 for sub-cohort A2. Study participants who
tested positive for S. haematobium were treated with
praziquantel (biltricide, lot number: 364415) at the
standard dose of 40 mg/kg body weight as recom-
mended by the WHO [4]. The drug was adminis-
tered orally after the child had eaten at least 4 slices
of bread with a cup of fruit juice. To ensure adher-
ence, every child took the tablets in front of the
research team members. Children that continued
excreting viable eggs in the urine 4 weeks after the
initial treatment received further treatment with
PZQ at the same dose of 40 mg/kg body weight.
They were re-screened after 4 weeks and those that
remained positive after the repeated treatment were
referred to the clinics for follow up.
Data management and statistical analysis
The SPSS 24 version was used for data analysis [33].
Positive S. haematobium infection was defined as a
sample with number of eggs greater than zero in
10 ml of urine. The number of infected children with
S. haematobium over the total number screened was
defined as prevalence. Intensity of infection was
classified as “light” for less than 50 eggs/10 ml and
“heavy” for equal or more than 50 eggs/10 ml for S.
haematobium [34]. As the assessment for PZQ
efficacy followed the same process in both cohorts
(A1 and A2) the results were pooled together for
interpretation. Efficacy was defined as an absence of eggs
in the specimen 4 weeks post treatment in participants
who initially tested positive. To assess the praziquan-
tel efficacy, cure rate (CR) and egg reduction rate
(ERR), the following formulae used in previous stud-
ies [35, 36] were used.
Since data were not normally distributed even after log
transformation, geometric means were calculated only
for positive values (greater than 0). Wilcoxon signed
ranks test was therefore used for comparison of geomet-
ric mean egg accounts.
Pearson Chi square test was performed to assess
the association between the infection intensity with
age and gender. It was also used to ascertain the as-
sociation of the re-infection and incidence rates with
the infection intensity, gender and the age. Partici-
pants that continued excreting viable eggs after they
had received PZQ treatment were regarded as drug
failure cases. Re-infection cases were defined as those
that were positive for schistosomiasis on the initial
examination and became negative on the second
examination reverting to positive on the subsequent
parasitology survey. Participants that became negative
after the administration of the second dose of PZQ
were excluded from the analysis.
Incidence was defined as the occurrence of new cases
of infection among those who tested negative at the ini-
tial parasitology survey. Children that tested positive
4 weeks after the initial parasitology survey were consid-
ered as pre-patent cases and were excluded from the
analysis. Considering the difference in the treatment
period, re-infection rate was assessed at 20 weeks post
treatment for cohort A1 at 28 weeks for cohort A2.
Children that had left school during the subsequent
surveys or withdrew from the study or failed to provide
urine specimens were excluded from the data analysis.
95% Confidence interval were used with P value < 0.05
as the statistical significance.
Results
Baseline parasitology
In the baseline parasitology survey, the mean age of
participants was 12.9 years. Out of the 320 screened
school-going children aged 10 – 15 years enrolled in the
study, 120 (37.5%) tested positive for S. haematobium
infection. 63 (60.8%) were females while 47 (39.2%) were
males. 44 (36.7%) had heavy infections with females
having the highest rate (54.5%).
13 and 14 years old participants had the highest rate
of heavy infection (25.5% each) as shown in Table 1.
However, the differences in intensity of infection be-
CR ¼ Number of negative children after treatment who where positive at baseline
Number of positive children before treatment
 100
ERR ¼ 1−Arithmetic mean egg counts per 10ml after treatment at baseline
Arithmetic mean egg counts before treatment
 
 100
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tween ages (χ2 = 4.886, P = 0.430) and males and females
(χ2 = 1.153, P = 0.283) were not significant.
Treatment and efficacy of praziquantel
Of the 120 infected school going children treated
with praziquantel, 29 were not at school during the
follow-up survey representing an attrition rate of
24.16%. They were therefore, excluded from the ana-
lysis. Ninety-one participants were screened for infec-
tion four weeks after they had received the first dose
of PZQ at 40 mg/Kg body weight (Table 2). Out of
the 91 children, 77 (84.62%) were cured; 43 (55.84%)
were females and 34 (44.16%) were males. However,
14 (15.38%) participants continued excreting viable
eggs. CR of 86% and ERR of 80% were found in
females while for males the same rates were 82.9%
and 64%, respectively following administration of the
first dose as shown in Table 2. Higher CR was ob-
served amongst 11 years old children (86.6%) while
failure rates were higher amongst 12, 13 and 14 years
old participants accounting for 4 children (28.6%) in
each group. All children that continued excreting eggs
14 (15.38%) had light infections. The arithmetic mean
decreased in both females and males from 103.04 to
2.08 and 99.13 to 3.61, respectively. Of the 14 cases
of treatment failure that received the second dose of
PZQ, 7 (50%) were re-screened. The other 7 had left
school, resulting in an attrition rate of 50.0%. The CR
was 100% in females compared to 50% in males with
a ERR of 100% in females and 78% (Table 2).
Comparison of the geometric mean of egg counts
comparison post administration of PZQ gave a Z value
of −1.572 with a P value of 0.116 between the baseline
and after the first dose; and a Z value of −0.447 with
a P value of 0.655 between the baseline and after the
second dose administration. No statistical significance
was found (P value > 0.05) between geometric means
of eggs for the different periods of intervention for
the efficacy assessment.
Re-infection
Table 3 shows that 37 children were re-screened to
determine the re-infection rate of which sub-cohort A1
accounted for 25 and sub-cohort A2 for 12. Of the 25
followed in sub-cohort A1, 23 (92.0%) participants
remained negative while 2 (8.0%) became infected
28 weeks post treatment and only females were infected.
In the sub-cohort A2, of the 12 screened children, 11
(91.7%) remained negative while only 1 (8.3%) child got
re-infected. Overall, out of the 37 children that were
cured for schistosomiasis, 34 (91.9%) remained negative
and 3 (8.1%) contracted the infection after treatment.
Eleven years old children had the highest cure rate while
12 years old were more affected but there was no statis-
tical significant difference (χ2 = 7.600, P = 0.107). Two
female participants were re-infected (66.7%) and this
was among those that had light infection at the baseline.
Incidence
At the baseline parasitology survey, 200 children tested
negative of which 171 participated in the follow up
survey. Hundred and eight were females and 63 were
males Of the 96 cases used to determine incidence, 92
(95.83%) remained negative for S. haematobium infec-
tion while 4 (4.17%) were new infections of which 3
(75%) were females (Table 4). Fifty percent of the new
infections were among 11 years old children but there
was no significant difference between the age (χ2 = 3.230,
P = 0.664).
Discussion
At baseline survey, Schistosoma haematobium infection
in the study area was relatively low (37.5%) compared to
68.8% prevalence reported 18 years ago [23]. The drastic
reduction of the prevalence was probably because of a
treatment programme targeting school-going children in
Table 2 Praziquantel efficacy (PZQ) against Schistosoma haematobium after the first and second treatment at 40 mg/kg
Gender Baseline 4 weeks after the 1st dose of PZQ 4 weeks after the 2nd dose of PZQ






CR AM/10 ml ERR No
Assessed
No cured No of
Failure
CR AM/10 ml ERR
Female 73 103.04 50 43 7 86.0 2.08 80 3 3 0 100 0 100
Male 47 99.13 41 34 7 82.9 3.61 64 4 2 2 50 22 78
CR= Cure Rate, ERR= Egg reduction rate, AM/10 ml Arithmetic Mean of egg counts per 10 ml urine
Table 1 Schistosoma haematobium infection intensity at
baseline amongst primary school-going children in Ndumo area,
uMkhanyakude district
Parameters Infection intensity χ2 P value
Light Heavy
Age 10 years 1 (1.3%) 1 (2.3%) 4.886 0.430
11 years 20 (26.3%) 6 (13.6%)
12 years 14 (18.4%) 6 (13.6%)
13 years 19 (25.0%) 11 (25.0%)
14 years 11 (14.5%) 11 (25.0%)
15 years 11 (14.5%) 9 (20.0%)
Gender Female 49 (64.5%) 24 (54.5%) 1.153 0.283
Male 27 (35.5%) 20 (45.5%)
Light infection: < 50 eggs/10 ml, Heavy: ≥ 50 eggs/10 ml
Kabuyaya et al. Infectious Diseases of Poverty  (2017) 6:83 Page 6 of 9
primary schools that has been implemented for 3 years
in the study area [24]. Our findings suggest that admin-
istration of praziquantel once every 2 years according to
the WHO recommendation [35] is appropriate for
Ndumo area. Females were more affected than males
and more likely to have contact with contaminated water
than males since fetching water and washing clothes are
considered as female duties in the study area [37]. Thir-
teen years and 14 years old children had the highest rate
of heavy infection that decreased with age. The findings
are consistent with those found in a similar study in
Ethiopia [38]. This may be attributed to intense water
contact activities that adolescents are usually involved in
but decreases with the age. Moreover, the study reported
heavier infections in females than in males. Our results
corroborate with those reported in a survey conducted
in Nigeria [39]. The fact that in rural communities,
females are more exposed to water contact activities
(fetching water from river/dam, washing clothes and
dishes) than males may explain these observations.
However, in other studies [38, 40] heavy infections were
predominantly recorded among males. This, however
depends on socio-environmental factors where the stud-
ies were conducted. For instance, a fishing community
where mainly men do the fishing might have more males
infected while in a community with market gardening
more women might be infected.
The CR and ERR in both females and males 4 weeks
post treatment suggested that the efficacy of praziquan-
tel after the first single standard dose was reduced.
Similar results were reported in studies conducted in
rural communities of Abeokuta of Nigeria [36], in
Senegal [41], and in Loum, Cameroun [42]. In contrast
to our findings, a study carried out in Zimbabwe found
satisfactory efficacy with praziquantel after the first dose
[43]. This might be because immature worms at first
treatment were not killed and reached their maturity
stage after treatment had been done. Thus, new mature
worms would have produced viable eggs after the treat-
ment. We found high treatment failures amongst 13 and
14 years old children with heavy intensity. CR and fail-
ure cases observed were consistent with findings in a
study conducted in Abeokuta, Nigeria [36]. A high load
of eggs in the urine indicates implicitly a high number of
mature worms, which may require a higher dose than
the standard dose. After the administration of the sec-
ond treatment with PZQ, females were completely cured
while CR remained low with ERR reduced in males.
There was a significant improvement in CR and ERR in
females compared to the outcome of the first dose. The
efficacy of PZQ remained low in males. This is contra-
dicts findings observed in others studies [36, 41] where
the CR and ERR were higher after the administration of
a second standard dose of PZQ than it was after the first
round. Parameters such as infection intensity [36], low
drug absorption, and high level of catabolism rather than
the resistance of parasite have been associated with low
efficacy of PZQ in endemic regions [43]. The findings in
this study showed no significant difference in geometric
mean egg counts at the different periods of treatment.
This might have been due to light intensity of the infec-
tion after the administration of the first dose.
During the follow-up of children that were cured, a low
re-infection rate was found (8.1%) 28 weeks post treat-
ment. The persistent drought throughout the study period
might explain our observations. Manyangadze et al. [43]
showed that a considerable number of the transmission
hotspots dried up during the study period, thus limiting
Table 3 Occurrence of re-infection cases of Schistosoma haematobium post-treatment amongst school-going children in Ndumo
area, KwaZulu-Natal
Cohort Gender Baseline 4 weeks post treatment Reinfection assessment












A1 (28 weeks) Female 49 36 13 (26.5) 32 (88.9) 4 (11.1) 17 15 (88.2) 2 (11.7)
Male 28 26 2 (7.1) 22 (84.6) 4 (15.3) 8 8 (100.0) 0 (0.0)
A2 (20 weeks) Female 24 14 10 (41.6) 11 (78.57) 3 (21.43) 5 5 (100.0) 0 (0.0)
Male 19 15 4 (21.0) 12 (80.0) 3 (20.0) 7 6 (85.7) 1 (14.3)
Total 120 91 29 (24.1) 77 (84.6) 14 (15.4) 37 34 (91.9) 3 (8.1%)
Table 4 Occurrence of new-infections of Schistosoma haematobium at 28 weeks amongst children in the Ndumo area
Gender Baseline Incidence assessment at 28 weeks
1st Screening 2nd Screening Prepatent Infection Negative Screened Attrition Rate Negative New Infection
Female 126 108 7 (6.4) 101 (93.6) 62 39 (36.1) 59 (95.2) 3 (4.8)
Male 74 63 6 (9.5) 57 (90.5) 34 25 (39.7) 33 (95.0) 1 (3.0)
Total 200 171 13 (7.6) 158 (92.4) 96 64 (37.4) 92 (95.9) 4 (4.1)
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the exposure of children to water contact. However, in
comparison to a study conducted in the area 18 years ago,
re-infection cases were observed only 41 weeks post
treatment and seemed to be limited to the hot and rainy
summer [23]. In contrast to our findings, other studies
observed a rapid and high re-infection rate a few weeks
following treatment [44]. In this case many factors have
been incriminated in the occurrence of high re-infection
rates such as ecological and seasonal factors [42], and
being an area with high intensity infection [22]. People
might get re-infected when they revert to their previous
daily activities involving contact with water infested with
snail intermediate hots after a successful treatment with
praziquantel.
Conclusions
The study showed a high CR and low ERR suggesting
low efficacy of PZQ which improved in females after the
second dose. An overall re-infection rate of 8.1% at 20
and 28 weeks post treatment was observed in the study
during a drought period. The study also indicated an
incidence rate of 4.1% over a period of 28 weeks. Since
the study area is a moderate zone of transmission with-
out any specific current control program, treatment with
PZQ once every 2 years may keep the infection at low
level of transmission. Moreover, while waiting for a more
efficacious drug than PZQ to come on the market, con-
trol programs may consider the use of the repeated
standard dose.
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